• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Donidalorsen reduces attacks in patients with hereditary angioedema

byMinjee Kim
April 13, 2022
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with hereditary angioedema receiving donidalorsen showed reduced rates of angioedema attacks compared to patients receiving placebo treatment.

2. Donidalorsen shows an acceptable safety profile after four doses.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Patients with hereditary angioedema experience unpredictable swellings that could potentially be fatal. Donidalorsen is an antisense oligonucleotide treatment that inhibits the production of plasma prekallikrein, a key contributor to excessive vascular permeability. In this phase 2 trial, patients with hereditary angioedema with C1 deficiency were randomized in a 2:1 ratio to either receive four doses of donidalorsen or placebo treatment. The primary endpoint was the number of confirmed angioedema attacks per month between experimental groups. Secondary endpoints analyzed the number of moderate-to-severe attacks, prekallikrein levels, and impact on quality of life measures. The study found that at a 17-week follow-up, patients receiving donidalorsen experienced a lower rate of investigator-confirmed angioedema attacks per month compared to patients receiving placebo. This group also experienced an improvement in quality of life measures and a reduction in prekallikrein activity. Safety data demonstrate similar rates of adverse events in both groups with the most common event being headache and nausea. Taken together, this study supports the use of donidalorsen as a treatment for patients with hereditary angioedema and warrants further investigation on its safety and efficacy. The study is limited by its very small sample size and selection of patients with C1 inhibitor deficiency, limiting the generalizability of these results to all patients with hereditary angioedema.

Click to read the study in NEJM 

RELATED REPORTS

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

Relevant Reading: Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema

In-Depth [randomized controlled trial]: In this small phase 2 randomized control trial, 20 patients with laboratory-confirmed hereditary angioedema with a C1 inhibitor deficiency (activity < 40%) were randomized in a 2:1 ratio to either receive 80 mg of donidalorsen or placebo treatment by subcutaneous injection on a schedule of 4 doses each spaced 4 weeks apart. Patients were then tracked for frequency and severity of investigator-confirmed angioedema attacks throughout the 17-week study. Secondary endpoints analyzed differences in frequency of moderate-to-severe attacks, attacks in the second half of the study, prekallikrein levels, and impact on quality of life measures. Differences in rates were analyzed using a Poisson regression model. The study found that the 14 patients who received donidalorsen had a mean monthly rate of 0.23 investigator-confirmed angioedema attacks (95% confidence interval [CI], 0.08 – 0.39), which was significantly lower than the 8 patients in the placebo group who had 2.21 (95% CI, 0.58 – 3.85). This represents a -90% mean difference between groups (95% CI, -96 to -76; P<0.001). With respect to secondary outcomes, patients receiving donidalorsen also demonstrate a reduction in moderate-to-severe attacks (-88%), decreased prekallikrein activity (-61%), and increased quality of life scores on the Angioedema Quality of Life Questionnaire. No serious adverse events were experienced by either group throughout the trial; however, mild adverse events were experienced by both groups with headache and nausea being the most common. Overall, the results of this small trial were able to support the use of donidalorsen in patients with hereditary angioedema and confirmed C1 inhibitor deficiency. Continued investigation for safety and efficacy in larger and longer trials is warranted.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: angioedemaangioedema attacksC1 inhibitorC1-inhibitor deficiencydonidalorsenhereditary angioedemakallikreinprekallikrein
Previous Post

Interatrial shunt device not effective in patients with symptomatic heart failure

Next Post

Sensorimotor religious and spiritual traditions may improve mental health outcomes

RelatedReports

Pharma

Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks

November 25, 2024
#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema
StudyGraphics

#VisualAbstract: Donidalorsen Every 4 or 8 Weeks Led to a Lower Monthly Attack Rate Than Placebo in Patients with Hereditary Angioedema

August 13, 2024
#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks
StudyGraphics

#VisualAbstract Sebetralstat Provides Faster Symptom Relief and Reduced Severity in Hereditary Angioedema Attacks

July 31, 2024
Chronic Disease

Oral sebetralstat provides early symptom relief for hereditary angioedema attacks

July 15, 2024
Next Post
Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Sensorimotor religious and spiritual traditions may improve mental health outcomes

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

Aspirin therapy linked to fewer cases of preeclampsia

Cessation of aspirin in older adults not associated with adverse health effects

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.